In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line

Background & objectives: Statins are one of the most widely used drugs and have antilipidemic effects as well as antioxidant, anti-inflammatory, anti-angiogenic and anti-tumorigenic effects. It has been shown that the synergistic combinations of statins which can provide better clinical benefit in the treatment of cancer and if administered with other anticancer agents, may be an alternative treatment modality. The aim of this study was to assess the efficacy of administrating statin in multiple myeloma (MM) cell line on cell proliferation. Methods: U266 myeloma cells were cultured in 25 or 75 cm[2] flasks by using cell culture medium mixtures obtained with the supplementation of 10 per cent foetal bovine serum and one per cent of penicillin-streptomycin into RPMI 1640 medium. When the cells reached confluence (reached to the density of 70%), they were reproduced by passaging. Cytotoxicity was evaluated by using the XTT test. Results: Statins (atorvastatin and simvastatin), were administered to the U266 myeloma cell line at 100, 50, 25, 12.5, 6.25 and 3.12 ?M concentrations. Inhibitor concentration 50 (IC50) values calculated for atorvastatin and simvastatin were determined as 94 and 38 ?M, respectively. While 100, 50, 25, 12.5, 6.25 and 3.12 ?M concentrations were used for bortezomib, the IC50value calculated for this agent was 18.2 nM. When six concentrations of bortezomib used in the study were combined with 12.5 ?M inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin. Interpretation & conclusions: Our in vitro results indicated that atorvastatin and simvastatin when used along with the conventional treatment in myeloma patients, may improve the effectiveness of the standard therapy and prevent the bortezomib-induced cytotoxic and neurotoxic side effects when used at a low dose. Further studies need to be done in MM patints to confirm these findings.

First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study

BACKGROUND/AIMS: The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70~85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. MATERIALS AND METHODS: Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy. RESULTS: This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001). CONCLUSIONS: Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.

Standard therapy of advanced colorectal cancer / 肿瘤研究与临床

The clinical guidelines of standard chemotherapy of metastatic colorectal cancer(mCRC) were mainly from the recommendation of national comprehensive cancer network(NCCN),CNCCN and euro- pean society for medical oncology(ESMO).The key to success of mCRC is how to understand and apply these clinical guidelines correctly.Along with the appearance of evidence by newer and better evidence-based medicine,there guidelines will be revised at any time.In the clinical application,the newest guideline should be used according to the practical status of our country,in order to imorove the therapeutic effect of mCRC.